Alliance Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET) Adult CIRB - Late Phase Emphasis Active Available to Open